Blog dermatologico

Elenco degli articoli con argomento «brodalumab»

Brodalumab Achieves Superior Lesion Clearance Compared With Secukinumab and Ustekinumab in Moderate-to-Severe Psoriasis

Rassegna stampa

More patients with moderate-to-severe psoriasis achieved "clear" or "almost clear" status with brodalumab than with secukinumab using Psoriasis Area and Severity (PASI) scores...

Leggi tutto

Brodalumab Shows Sustained Efficacy in Treating Moderate-to-Severe Psoriasis

Rassegna stampa

Brodalumab achieved high levels of lesion clearance in the majority of patients with moderate-to-severe psoriasis, with results sustained through 120 weeks...

Leggi tutto

Switching to Brodalumab From Ustekinumab Improves Clearance in Moderate-to-Severe Psoriasis

Rassegna stampa

Patients with moderate-to-severe psoriasis that did not adequately respond to ustekinumab achieve high levels of lesion clearance after switching to brodalumab rescue therapy...

Leggi tutto

FDA Approves Brodalumab to Treat Psoriasis

Rassegna stampa

The US Food and Drug Administration (FDA) has approved brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab is administered as an injection....

Leggi tutto

Investigational Drug Brodalumab Effective for Patients With Psoriasis

Rassegna stampa

An experimental, biologic treatment, brodalumab, appears to be more effective than ustekinumab in reducing psoriasis symptoms...

Leggi tutto